Xenetic Biosciences, Inc. (XBIO)

Xenetic Biosciences Statistics

Total Valuation

XBIO has a market cap or net worth of $4.67 million. The enterprise value is -$107,165.

Market Cap	4.67M
Enterprise Value	-107,165

Important Dates

The last earnings date was Wednesday, August 13, 2025, before market open.

Earnings Date	Aug 13, 2025
Ex-Dividend Date	n/a

Share Statistics

XBIO has 1.54 million shares outstanding. The number of shares has increased by 0.25% in one year.

Current Share Class	1.54M
Shares Outstanding	1.54M
Shares Change (YoY)	+0.25%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	6.89%
Owned by Institutions (%)	4.80%
Float	1.18M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.91
Forward PS	3.47
PB Ratio	1.05
P/TBV Ratio	1.05
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.93

Current Ratio	5.93
Quick Ratio	5.29
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -51.83% and return on invested capital (ROIC) is -34.31%.

Return on Equity (ROE)	-51.83%
Return on Assets (ROA)	-28.37%
Return on Invested Capital (ROIC)	-34.31%
Return on Capital Employed (ROCE)	-73.38%
Revenue Per Employee	$1.22M
Profits Per Employee	-$1.54M
Employee Count	2
Asset Turnover	0.34
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -25.74% in the last 52 weeks. The beta is 2.33, so XBIO's price volatility has been higher than the market average.

Beta (5Y)	2.33
52-Week Price Change	-25.74%
50-Day Moving Average	3.33
200-Day Moving Average	3.53
Relative Strength Index (RSI)	47.33
Average Volume (20 Days)	32,882

Short Selling Information

The latest short interest is 43,583, so 2.83% of the outstanding shares have been sold short.

Short Interest	43,583
Short Previous Month	32,752
Short % of Shares Out	2.83%
Short % of Float	3.68%
Short Ratio (days to cover)	0.77

Income Statement

In the last 12 months, XBIO had revenue of $2.45 million and -$3.08 million in losses. Loss per share was -$2.00.

Revenue	2.45M
Gross Profit	2.45M
Operating Income	-3.27M
Pretax Income	-4.47M
Net Income	-3.08M
EBITDA	n/a
EBIT	-3.27M
Loss Per Share	-$2.00

Balance Sheet

The company has $4.78 million in cash and n/a in debt, giving a net cash position of $4.78 million or $3.10 per share.

Cash & Cash Equivalents	4.78M
Total Debt	n/a
Net Cash	4.78M
Net Cash Per Share	$3.10
Equity (Book Value)	4.45M
Book Value Per Share	2.88
Working Capital	4.45M

Cash Flow

Operating Cash Flow	-2.52M
Capital Expenditures	n/a
Free Cash Flow	-2.52M
FCF Per Share	-$1.63

Margins

Gross margin is 100.00%, with operating and profit margins of -133.49% and -126.03%.

Gross Margin	100.00%
Operating Margin	-133.49%
Pretax Margin	-126.03%
Profit Margin	-126.03%
EBITDA Margin	n/a
EBIT Margin	-133.49%
FCF Margin	n/a

Dividends & Yields

XBIO does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.25%
Shareholder Yield	-0.25%
Earnings Yield	-65.98%
FCF Yield	-53.90%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	Hold
Analyst Count	1
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 15, 2023. It was a reverse split with a ratio of 1:10.

Last Split Date	May 15, 2023
Split Type	Reverse
Split Ratio	1:10

Scores

XBIO has an Altman Z-Score of -48.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-48.75
Piotroski F-Score	3